IBDEI1G0 ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,24514,0)
 ;;=T1016^^91^1085^2^^^^1
 ;;^UTILITY(U,$J,358.3,24514,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,24514,1,2,0)
 ;;=2^T1016
 ;;^UTILITY(U,$J,358.3,24514,1,3,0)
 ;;=3^Case Management per 15min
 ;;^UTILITY(U,$J,358.3,24515,0)
 ;;=96372^^91^1086^1^^^^1
 ;;^UTILITY(U,$J,358.3,24515,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,24515,1,2,0)
 ;;=2^96372
 ;;^UTILITY(U,$J,358.3,24515,1,3,0)
 ;;=3^Ther/Proph/Diag Inj SC/IM
 ;;^UTILITY(U,$J,358.3,24516,0)
 ;;=96374^^91^1086^2^^^^1
 ;;^UTILITY(U,$J,358.3,24516,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,24516,1,2,0)
 ;;=2^96374
 ;;^UTILITY(U,$J,358.3,24516,1,3,0)
 ;;=3^Ther/Proph/Diag Inj IV Push
 ;;^UTILITY(U,$J,358.3,24517,0)
 ;;=96376^^91^1086^3^^^^1
 ;;^UTILITY(U,$J,358.3,24517,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,24517,1,2,0)
 ;;=2^96376
 ;;^UTILITY(U,$J,358.3,24517,1,3,0)
 ;;=3^Tx/Pro/Dx Inj,ea addl sequential IVP of Same Drug-Add-on
 ;;^UTILITY(U,$J,358.3,24518,0)
 ;;=J2680^^91^1087^1^^^^1
 ;;^UTILITY(U,$J,358.3,24518,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,24518,1,2,0)
 ;;=2^J2680
 ;;^UTILITY(U,$J,358.3,24518,1,3,0)
 ;;=3^Fluphenazine Decanoate up to 25mg
 ;;^UTILITY(U,$J,358.3,24519,0)
 ;;=J1631^^91^1087^2^^^^1
 ;;^UTILITY(U,$J,358.3,24519,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,24519,1,2,0)
 ;;=2^J1631
 ;;^UTILITY(U,$J,358.3,24519,1,3,0)
 ;;=3^Haloperidol Decanoate per 50mg
 ;;^UTILITY(U,$J,358.3,24520,0)
 ;;=J2315^^91^1087^3^^^^1
 ;;^UTILITY(U,$J,358.3,24520,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,24520,1,2,0)
 ;;=2^J2315
 ;;^UTILITY(U,$J,358.3,24520,1,3,0)
 ;;=3^Naltrexone,Depot Form 1mg
 ;;^UTILITY(U,$J,358.3,24521,0)
 ;;=J2426^^91^1087^4^^^^1
 ;;^UTILITY(U,$J,358.3,24521,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,24521,1,2,0)
 ;;=2^J2426
 ;;^UTILITY(U,$J,358.3,24521,1,3,0)
 ;;=3^Paliperidone Palmitate Extend Release per 1mg
 ;;^UTILITY(U,$J,358.3,24522,0)
 ;;=J2794^^91^1087^5^^^^1
 ;;^UTILITY(U,$J,358.3,24522,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,24522,1,2,0)
 ;;=2^J2794
 ;;^UTILITY(U,$J,358.3,24522,1,3,0)
 ;;=3^Risperidone Long Act per 0.5mg
 ;;^UTILITY(U,$J,358.3,24523,0)
 ;;=J2315^^91^1087^6^^^^1
 ;;^UTILITY(U,$J,358.3,24523,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,24523,1,2,0)
 ;;=2^J2315
 ;;^UTILITY(U,$J,358.3,24523,1,3,0)
 ;;=3^Vivitrol 1mg
 ;;^UTILITY(U,$J,358.3,24524,0)
 ;;=96150^^91^1088^1^^^^1
 ;;^UTILITY(U,$J,358.3,24524,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,24524,1,2,0)
 ;;=2^96150
 ;;^UTILITY(U,$J,358.3,24524,1,3,0)
 ;;=3^Behavior/Health Init Assm,Ea 15min
 ;;^UTILITY(U,$J,358.3,24525,0)
 ;;=96151^^91^1088^2^^^^1
 ;;^UTILITY(U,$J,358.3,24525,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,24525,1,2,0)
 ;;=2^96151
 ;;^UTILITY(U,$J,358.3,24525,1,3,0)
 ;;=3^Behavior/Health Re-Assm,Ea 15min
 ;;^UTILITY(U,$J,358.3,24526,0)
 ;;=99211^^92^1089^1
 ;;^UTILITY(U,$J,358.3,24526,1,0)
 ;;=^358.31IA^1^1
 ;;^UTILITY(U,$J,358.3,24526,1,1,0)
 ;;=1^Nursing Only Visit
 ;;^UTILITY(U,$J,358.3,24527,0)
 ;;=T74.11XA^^93^1090^5
 ;;^UTILITY(U,$J,358.3,24527,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24527,1,3,0)
 ;;=3^Adult Physical Abuse,Confirmed,Initial Encounter  
 ;;^UTILITY(U,$J,358.3,24527,1,4,0)
 ;;=4^T74.11XA
 ;;^UTILITY(U,$J,358.3,24527,2)
 ;;=^5054146
 ;;^UTILITY(U,$J,358.3,24528,0)
 ;;=T74.11XD^^93^1090^6
 ;;^UTILITY(U,$J,358.3,24528,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,24528,1,3,0)
 ;;=3^Adult Physical Abuse,Confirmed,Subsequent Encounter 
 ;;^UTILITY(U,$J,358.3,24528,1,4,0)
 ;;=4^T74.11XD
 ;;^UTILITY(U,$J,358.3,24528,2)
 ;;=^5054147
 ;;^UTILITY(U,$J,358.3,24529,0)
 ;;=T76.11XA^^93^1090^7
